Tools
Stock profile

TAKEDA PHARMACEUTICAL CO LTD (TAK)

TAK · Latest close $21.27 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$21.27
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

TAKEDA PHARMACEUTICAL CO LTD (TAK) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $5.3M sold). Latest close $21.27 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 4, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-5.3M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Pzena Investment Management — 1 tracked fund hold TAK. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 5 sales ($5.3M). Insider trading

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Pzena Investment Management<0.01%37,820ADDED (+33.4%) Q3 filed Oct 30

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +35.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

21.6412.542024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding377 of 8,857 filers
Long-only filers among them375
Change vs 2026 Q1+20 net · 356 entered · 336 exited
Shares reported, all filers104,137,768
Reported value, all filers$1.7B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY20254,581.6B JPY
Net income · FY2025108.1B JPY
Total assets · FY202514,248.3B JPY

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026.

Short interest

Shares short · Oct 15, 20263,289,262
Days to cover1.09

Shares short at recent settlements — Jul 31, 2026: 2.9M · Aug 14, 2026: 3.0M · Aug 31, 2026: 4.1M · Sep 15, 2026: 4.2M · Sep 30, 2026: 2.9M · Oct 15, 2026: 3.3M.

Source: FINRA Equity Short Interest (biweekly settlement data).

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 5 sales by 4 insiders ($5.3M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 4, 2026Platford Giles RichardPresident, IBUSell55,617$20.90$1.2MSEC filing
Nov 2, 2026Bitetti Teresa MariePresident, OBUSell46,609$20.89$973.7KSEC filing
Sep 14, 2026Duprey Lauren RusckowskiChief Transformation OfficerSell34,535$18.54$640.3KSEC filing
Sep 2, 2026Plump Andrew StewartPresident, R&DSell116,191$18.49$2.1MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 10, 2026Lauren Rusckowski DupreyChief Transformation Officer34,535$634.4KSep 10, 2026SEC filing
Sep 2, 2026Plump Andrew StewartOfficer116,191$2.1MSep 2, 2026SEC filing
Aug 19, 2026Plump Andrew StewartOfficer19,651$363.3KAug 19, 2026SEC filing
Aug 14, 2026Nicola GreenwayChief Human Resources Officer12,980$225.7KAug 14, 2026SEC filing
Aug 10, 2026Elaine ShannonPresident, Global Supply & Quality20,363$355.3KAug 11, 2026SEC filing
Aug 6, 2026Nicola GreenwayChief Human Resources Officer34,603$578.6KAug 7, 2026SEC filing
Jul 13, 2026Marcello Pignagnoli AgostiInterim Head, Strategy and Portfolio Development24,887$416.9KJul 13, 2026SEC filing
Jul 13, 2026Lauren Rusckowski DupreyChief Transformation Officer51,579$863.9KJul 13, 2026SEC filing
Jul 13, 2026Giles PlatfordPresident, International Business Unit33,696$564.4KJul 13, 2026SEC filing
Jul 13, 2026Natalie FurneyGlobal General Counsel33,454$560.4KJul 13, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· 52-Week High — Recently printed a new 52-week high

· Top Relative Strength — Top 20% of the universe by 6-month return

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold TAK — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

No Form 8-K filings for this ticker in the index (Jan 2023 – present).

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on TAK

One email a week: the week’s new filings and research. Subscribe free

← TAC  ·  TAL →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.